Researchers assess whether GLP-1 receptor agonists increase the risk of suicide, self-harm, or suicidal ideation in type 2 ...

In older adults with diabetes, GLP-1 receptor agonists were tied to a slightly lower risk for depression compared with one ...

Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class ...

Consumers taking GLP-1 drugs like Ozempic will need to adapt their shopping habits and diets, opening opportunities for food ...

Evidence suggests no increased risk The use of glucagon-like peptide-1 (GLP-1) receptor agonists has surged in recent years, driven by their benefits in glucose control in type 2 diabetes, weight ...

Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications widely used in the treatment of type 2 diabetes (T2D), have ...

In recent years, the landscape of diabetes and weight management has been significantly altered by the rise of glucagon-like peptide-1 (GLP-1) receptor agonists. These medications, initially developed ...

Risk of suicidality wasn't higher for type 2 diabetes patients starting on GLP-1 receptor agonists than for those on two ...

For older adults with type 2 diabetes (T2D), use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with ...

Treatment for OUD is currently dominated by opioid agonist therapies that are highly regulated due to their liability for ...

While one study found lower rates of preterm birth alongside higher rates of hypertensive disorders, another found fewer ...

Opens in a new tab or window Older adults with type 2 diabetes newly treated with a GLP-1 receptor agonist had a lower risk for depression than DPP-4 inhibitor users. There was no difference for ...